ATE514091T1 - Verwendung von procalcitonin (pct) zur risikostratifikation und prognose bei patienten mit einer primären nichtinfektiösen krankheit - Google Patents
Verwendung von procalcitonin (pct) zur risikostratifikation und prognose bei patienten mit einer primären nichtinfektiösen krankheitInfo
- Publication number
- ATE514091T1 ATE514091T1 AT08786791T AT08786791T ATE514091T1 AT E514091 T1 ATE514091 T1 AT E514091T1 AT 08786791 T AT08786791 T AT 08786791T AT 08786791 T AT08786791 T AT 08786791T AT E514091 T1 ATE514091 T1 AT E514091T1
- Authority
- AT
- Austria
- Prior art keywords
- procalcitonin
- prognosis
- pct
- infectious disease
- patients
- Prior art date
Links
- 108010048233 Procalcitonin Proteins 0.000 title abstract 4
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 title abstract 4
- 208000031662 Noncommunicable disease Diseases 0.000 title abstract 2
- 238000004393 prognosis Methods 0.000 title abstract 2
- 238000013517 stratification Methods 0.000 title abstract 2
- 238000000338 in vitro Methods 0.000 abstract 2
- 238000003556 assay Methods 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 239000010839 body fluid Substances 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/585—Calcitonins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07015271A EP2020603A1 (de) | 2007-08-03 | 2007-08-03 | Verfahren zur Einteilung von Risikoklassen bei stabiler Erkrankung der Koronaraterien |
| EP08152651A EP2101178A1 (de) | 2008-03-12 | 2008-03-12 | Verwendung von Procalcitonin zur Prognose folgender akuter Koronarsyndromen |
| PCT/EP2008/060176 WO2009019230A2 (en) | 2007-08-03 | 2008-08-01 | Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE514091T1 true ATE514091T1 (de) | 2011-07-15 |
Family
ID=39745280
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT10188288T ATE533061T1 (de) | 2007-08-03 | 2008-08-01 | Verfahren zur diagnose bakterieller infektionen |
| AT08786791T ATE514091T1 (de) | 2007-08-03 | 2008-08-01 | Verwendung von procalcitonin (pct) zur risikostratifikation und prognose bei patienten mit einer primären nichtinfektiösen krankheit |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT10188288T ATE533061T1 (de) | 2007-08-03 | 2008-08-01 | Verfahren zur diagnose bakterieller infektionen |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20110136161A1 (de) |
| EP (4) | EP2174143B1 (de) |
| JP (2) | JP5059943B2 (de) |
| CN (3) | CN110346577A (de) |
| AT (2) | ATE533061T1 (de) |
| DE (1) | DE602008021800C5 (de) |
| ES (3) | ES2401703T3 (de) |
| WO (1) | WO2009019230A2 (de) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE533061T1 (de) | 2007-08-03 | 2011-11-15 | Brahms Gmbh | Verfahren zur diagnose bakterieller infektionen |
| HUE046182T2 (hu) * | 2009-04-14 | 2020-02-28 | Brahms Gmbh | Az antibiotikumos kezelés kozkázatának becslése elsõdlegesen nem fertõzõ betegségben szenvedõ betegekben a prokalcitonin szintjének meghatározásával |
| JP5731489B2 (ja) * | 2009-06-05 | 2015-06-10 | ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸困難を起こした患者における細菌感染の検出 |
| US20120149131A1 (en) | 2009-08-28 | 2012-06-14 | B.R.A.H.M.S Gmbh | Procalcitonin for the prognosis of adverse events |
| ES2601104T3 (es) * | 2009-10-13 | 2017-02-14 | B.R.A.H.M.S Gmbh | Procalcitonina para el diagnóstico de infecciones bacterianas y la guía del tratamiento antibiótico en pacientes con apoplejía aguda o accidente isquémico transitorio |
| US20130096052A1 (en) * | 2010-03-08 | 2013-04-18 | B.R.A.H.M.S Gmbh | Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with non-specific complaints |
| ITRM20100121A1 (it) * | 2010-03-18 | 2011-09-19 | Univ Pisa | Marcatori molecolari per infezioni delle vie urinarie. |
| BR112012032389A2 (pt) * | 2010-06-18 | 2016-10-25 | Brahms Gmbh | biomarcadores para a previsão de câncer incidente |
| US20130024205A1 (en) * | 2011-07-18 | 2013-01-24 | International Business Machines Corporation | Dynamically updating electronic medical records and leveraging a person's path in a facility to mitgate risks |
| AU2013217935B2 (en) | 2012-02-09 | 2018-05-17 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections and methods of use thereof |
| IN2014MN02101A (de) * | 2012-04-12 | 2015-08-28 | Brahms Gmbh | |
| AU2013262515B2 (en) * | 2012-05-18 | 2018-03-15 | Cardiac Pacemakers, Inc. | Methods for treating or predicting risk of a ventricular tachyarrhythmia event |
| MX358541B (es) | 2012-08-16 | 2018-08-24 | Critical Care Diagnostics Inc | Metodos para predecir el riesgo de desarrollar hipertension. |
| CN104937418B (zh) * | 2012-11-15 | 2019-08-23 | 奥索临床诊断有限公司 | 使用反应时间的校准分析 |
| RU2730836C2 (ru) | 2014-08-14 | 2020-08-26 | Мемед Диагностикс Лтд. | Вычислительный анализ биологических данных с применением многообразия и гиперплоскости |
| US20170234873A1 (en) | 2014-10-14 | 2017-08-17 | Memed Diagnostics Ltd. | Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof |
| EP3230740B1 (de) | 2014-12-11 | 2025-05-21 | Memed Diagnostics Ltd. | Markerkombinationen zur diagnose von infektionen und verfahren zur verwendung davon |
| CA3012985A1 (en) | 2015-01-27 | 2016-08-04 | Kardiatonos, Inc. | Biomarkers of vascular disease |
| JPWO2016199180A1 (ja) * | 2015-06-09 | 2018-04-12 | 国立大学法人大阪大学 | 生物学的製剤による関節リウマチの治療効果の予測判定方法 |
| CA3015046A1 (en) | 2016-03-03 | 2017-09-08 | Memed Diagnostics Ltd. | Rna determinants for distinguishing between bacterial and viral infections |
| WO2017149547A1 (en) | 2016-03-03 | 2017-09-08 | Memed Diagnostics Ltd. | Analyzing rna for diagnosing infection type |
| CN106093416B (zh) * | 2016-05-18 | 2018-10-12 | 北京北方生物技术研究所有限公司 | 一种一步法检测降钙素原的试剂盒及其制备方法 |
| WO2018011796A1 (en) | 2016-07-10 | 2018-01-18 | Memed Diagnostics Ltd. | Early diagnosis of infections |
| WO2018011795A1 (en) | 2016-07-10 | 2018-01-18 | Memed Diagnostics Ltd. | Protein signatures for distinguishing between bacterial and viral infections |
| WO2018060999A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of risk assessment and disease classification |
| WO2018060998A1 (en) | 2016-09-29 | 2018-04-05 | Memed Diagnostics Ltd. | Methods of prognosis and treatment |
| EP4027145A1 (de) * | 2017-09-13 | 2022-07-13 | B.R.A.H.M.S GmbH | Pro-adm zur therapieüberwachung von intensivpatienten |
| WO2019122088A1 (en) * | 2017-12-20 | 2019-06-27 | B.R.A.H.M.S Gmbh | Antibiotic therapy guidance based on procalcitonin in patients with comorbidities |
| US11446009B2 (en) | 2018-12-11 | 2022-09-20 | Eko.Ai Pte. Ltd. | Clinical workflow to diagnose heart disease based on cardiac biomarker measurements and AI recognition of 2D and doppler modality echocardiogram images |
| US12001939B2 (en) | 2018-12-11 | 2024-06-04 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI)-based guidance for an ultrasound device to improve capture of echo image views |
| US11931207B2 (en) | 2018-12-11 | 2024-03-19 | Eko.Ai Pte. Ltd. | Artificial intelligence (AI) recognition of echocardiogram images to enhance a mobile ultrasound device |
| US12400762B2 (en) | 2018-12-11 | 2025-08-26 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and diagnosis of cardiac amyloidosis and hypertrophic cardiomyopathy |
| US12322100B2 (en) | 2018-12-11 | 2025-06-03 | Eko.Ai Pte. Ltd. | Automatic clinical workflow that recognizes and analyzes 2D and doppler modality echocardiogram images for automated cardiac measurements and grading of aortic stenosis severity |
| WO2021062298A1 (en) | 2019-09-27 | 2021-04-01 | Arterez, Inc. | Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption |
| CN116762011A (zh) * | 2020-12-02 | 2023-09-15 | 贝克曼库尔特有限公司 | 发展成脓毒症的概率的检测 |
| CN117597584A (zh) | 2021-04-30 | 2024-02-23 | 豪夫迈·罗氏有限公司 | 用于脓毒症的早期检测的esm1标志物组合 |
| EP4330685A2 (de) | 2021-04-30 | 2024-03-06 | Roche Diagnostics GmbH | Ngal marker panels zur frühen erkennung von sepsis |
| EP4330684A2 (de) | 2021-04-30 | 2024-03-06 | F. Hoffmann-La Roche AG | Gdf15-markertafeln zur frühen erkennung von sepsis |
| CN117255947A (zh) | 2021-04-30 | 2023-12-19 | 豪夫迈·罗氏有限公司 | 用于脓毒症的早期检测的sFlt1标志物组 |
| JP2024516680A (ja) | 2021-04-30 | 2024-04-16 | エフ． ホフマン－ラ ロシュ アーゲー | 敗血症の早期検出用のｉｌ６マーカーパネル |
| JP2024516679A (ja) | 2021-04-30 | 2024-04-16 | エフ． ホフマン－ラ ロシュ アーゲー | 敗血症の早期検出用のｉｇｆｂｐ７マーカーパネル |
| US20240230672A1 (en) | 2021-04-30 | 2024-07-11 | Roche Diagnostics Gmbh | Presepsin marker panels for early detection of sepsis |
| CN117255948A (zh) | 2021-04-30 | 2023-12-19 | 豪夫迈·罗氏有限公司 | 用于脓毒症的早期检测的pct标志物组 |
| US20240230674A1 (en) | 2021-04-30 | 2024-07-11 | Roche Diagnostics Operations, Inc. | Strem1 marker panels for early detection of sepsis |
| WO2023052446A1 (en) | 2021-09-29 | 2023-04-06 | F. Hoffmann-La Roche Ag | Mr-proadm marker panels for early detection of sepsis |
| EP4483186A1 (de) | 2022-02-21 | 2025-01-01 | F. Hoffmann-La Roche AG | Dll1-markertafeln für den frühen nachweis von sepsis |
| EP4357778A1 (de) | 2022-10-20 | 2024-04-24 | Heraeus Medical GmbH | Behandlung von mikrobiellen infektionen mit diagnose durch biomarker d-lactat |
| CN119306832B (zh) * | 2023-07-11 | 2025-08-08 | 东莞市朋志生物科技有限公司 | 抗降钙素原抗体、检测降钙素原的试剂和试剂盒 |
| US20260102478A1 (en) * | 2024-10-14 | 2026-04-16 | Longhorn Vaccines And Diagnostics, Llc | Vaccines and Antibodies for the Treatment and Prevention of Neurodegenerative Disorders and Inflammation Related Health Conditions |
| WO2026119954A1 (en) | 2024-12-05 | 2026-06-11 | Roche Diagnostics Gmbh | Ppbp marker for early detection of sepsis |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4227454C1 (de) * | 1992-08-19 | 1994-02-03 | Henning Berlin Gmbh | Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens |
| US6147688A (en) | 1993-06-28 | 2000-11-14 | Athena Design Systems, Inc. | Method and apparatus for defining and selectively repeating unit image cells |
| US5795725A (en) | 1995-04-18 | 1998-08-18 | Biosite Diagnostics Incorporated | Methods for the assay of troponin I and T and selection of antibodies for use in immunoassays |
| DE19600875C1 (de) | 1996-01-12 | 1997-06-26 | Brahms Diagnostica Gmbh | Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse |
| US6156521A (en) | 1997-12-19 | 2000-12-05 | Biosite Diagnostics, Inc. | Methods for the recovery and measurement of troponin complexes |
| US5993811A (en) * | 1997-02-03 | 1999-11-30 | Biology Associates, Llc | Method and compositions for preventing and treating the systemic inflammatory response syndrome including sepsis |
| US5947124A (en) | 1997-03-11 | 1999-09-07 | Biosite Diagnostics Incorporated | Diagnostic for determining the time of a heart attack |
| DE19903336C2 (de) | 1999-01-28 | 2000-12-14 | Brahms Diagnostica Gmbh | Gebrauchsfertige Kalibratoren für die Bestimmung von Procalcitonin |
| US7632647B2 (en) | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
| US20040253637A1 (en) * | 2001-04-13 | 2004-12-16 | Biosite Incorporated | Markers for differential diagnosis and methods of use thereof |
| US7713705B2 (en) * | 2002-12-24 | 2010-05-11 | Biosite, Inc. | Markers for differential diagnosis and methods of use thereof |
| EP1322957B1 (de) * | 2001-05-04 | 2009-08-12 | Biosite Incorporated | Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs |
| JP2006526140A (ja) | 2002-12-24 | 2006-11-16 | バイオサイト インコーポレイテッド | 鑑別診断のためのマーカーおよびその使用方法 |
| DE10316583A1 (de) * | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
| CA2522709A1 (en) | 2003-04-17 | 2004-11-04 | Ciphergen Biosystems, Inc. | Polypeptides related to natriuretic peptides and methods of their identification and use |
| US20050148029A1 (en) | 2003-09-29 | 2005-07-07 | Biosite, Inc. | Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes |
| DE112004001863T5 (de) * | 2003-10-03 | 2006-09-07 | Scantibodies Laboratory, Inc., Santee | Verfahren und Verwendung von Bindungskomponenten zur Verbesserung der Testspezifität |
| CA2485722A1 (en) | 2003-10-22 | 2005-04-22 | Paul Lehmann | Soluble transferrin receptor |
| ATE312351T1 (de) | 2004-02-13 | 2005-12-15 | Brahms Ag | Verfahren zur bestimmung der bildung von endothelinen zu zwecken der medizinischen diagnostik, sowie antikörper und kits für die durchführung eines solchen verfahrens |
| US20060024744A1 (en) | 2004-07-28 | 2006-02-02 | Mills Rhonda A | Methods for substantially simultaneous evaluation of a sample containing a cellular target and a soluble analyte |
| DE102004041659A1 (de) | 2004-08-27 | 2006-03-02 | Institut Virion/Serion Gmbh | Testvorrichtung für die in vitro Diagnostik von Multianalyt-Tests und deren Verwendung |
| CN101213451B (zh) | 2005-06-28 | 2013-04-03 | Zbx公司 | 膜阵列和分析设备 |
| DE102005034174A1 (de) | 2005-07-21 | 2007-02-08 | B.R.A.H.M.S Ag | Liquordiagnostisches in vitro Verfahren zur Diagnose von Demenz-Erkrankungen und neuroinflammatorischen Erkrankungen |
| CA2624569A1 (en) * | 2005-10-03 | 2007-04-12 | Biosite Incorporated | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes |
| CN1800384A (zh) * | 2005-11-08 | 2006-07-12 | 浙江大学 | 降钙素原的制备方法 |
| EP2005168A4 (de) | 2006-03-09 | 2009-05-20 | Biosite Inc | Verfahren und zusammensetzung zur diagnose von krankheiten der aorta |
| DE102006046996A1 (de) * | 2006-10-01 | 2008-04-03 | Brahms Aktiengesellschaft | Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz |
| EP2020603A1 (de) | 2007-08-03 | 2009-02-04 | BRAHMS Aktiengesellschaft | Verfahren zur Einteilung von Risikoklassen bei stabiler Erkrankung der Koronaraterien |
| ATE533061T1 (de) * | 2007-08-03 | 2011-11-15 | Brahms Gmbh | Verfahren zur diagnose bakterieller infektionen |
| DE102008037108A1 (de) | 2008-08-08 | 2010-02-11 | Samson Aktiengesellschaft | System zum Stellen eines Stellorgans |
| ES2601104T3 (es) * | 2009-10-13 | 2017-02-14 | B.R.A.H.M.S Gmbh | Procalcitonina para el diagnóstico de infecciones bacterianas y la guía del tratamiento antibiótico en pacientes con apoplejía aguda o accidente isquémico transitorio |
| US20110263438A1 (en) | 2010-04-22 | 2011-10-27 | Mehmet Ali Soylemez | Diagnosis and complication risk assessment of pancreatic diabetes using procalcitonin |
-
2008
- 2008-08-01 AT AT10188288T patent/ATE533061T1/de active
- 2008-08-01 CN CN201910283751.1A patent/CN110346577A/zh active Pending
- 2008-08-01 ES ES10188289T patent/ES2401703T3/es active Active
- 2008-08-01 DE DE602008021800.7A patent/DE602008021800C5/de active Active
- 2008-08-01 AT AT08786791T patent/ATE514091T1/de active
- 2008-08-01 CN CN200880101846A patent/CN101790687A/zh active Pending
- 2008-08-01 ES ES10188288T patent/ES2377112T3/es active Active
- 2008-08-01 CN CN201210451017.XA patent/CN103123359B/zh active Active
- 2008-08-01 EP EP08786791A patent/EP2174143B1/de active Active
- 2008-08-01 US US12/671,702 patent/US20110136161A1/en not_active Abandoned
- 2008-08-01 WO PCT/EP2008/060176 patent/WO2009019230A2/en not_active Ceased
- 2008-08-01 EP EP10188287A patent/EP2301626B1/de active Active
- 2008-08-01 ES ES10188287T patent/ES2403310T3/es active Active
- 2008-08-01 EP EP10188289A patent/EP2293076B1/de active Active
- 2008-08-01 JP JP2010518695A patent/JP5059943B2/ja active Active
- 2008-08-01 EP EP10188288A patent/EP2293078B1/de active Active
-
2011
- 2011-02-25 US US13/034,752 patent/US10456364B2/en active Active
-
2012
- 2012-08-02 JP JP2012171897A patent/JP5185460B2/ja active Active
-
2019
- 2019-03-29 US US16/369,966 patent/US11241395B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10456364B2 (en) | 2019-10-29 |
| US20110136161A1 (en) | 2011-06-09 |
| ES2377112T3 (es) | 2012-03-22 |
| US20110152170A1 (en) | 2011-06-23 |
| EP2293078B1 (de) | 2011-11-09 |
| EP2301626A2 (de) | 2011-03-30 |
| JP2010536012A (ja) | 2010-11-25 |
| CN103123359A (zh) | 2013-05-29 |
| JP5059943B2 (ja) | 2012-10-31 |
| CN103123359B (zh) | 2015-07-29 |
| CN101790687A (zh) | 2010-07-28 |
| WO2009019230A3 (en) | 2009-04-23 |
| ES2401703T3 (es) | 2013-04-23 |
| JP5185460B2 (ja) | 2013-04-17 |
| CN110346577A (zh) | 2019-10-18 |
| EP2293078A2 (de) | 2011-03-09 |
| EP2301626A3 (de) | 2011-11-16 |
| EP2293076A3 (de) | 2011-03-30 |
| EP2301626B1 (de) | 2013-01-16 |
| US11241395B2 (en) | 2022-02-08 |
| ES2403310T3 (es) | 2013-05-17 |
| EP2293076B1 (de) | 2012-12-19 |
| ATE533061T1 (de) | 2011-11-15 |
| WO2009019230A4 (en) | 2009-06-25 |
| JP2012237760A (ja) | 2012-12-06 |
| EP2293076A2 (de) | 2011-03-09 |
| EP2174143B1 (de) | 2011-06-22 |
| WO2009019230A2 (en) | 2009-02-12 |
| EP2174143A2 (de) | 2010-04-14 |
| HK1183707A1 (en) | 2014-01-03 |
| EP2293078A3 (de) | 2011-04-06 |
| US20190224135A1 (en) | 2019-07-25 |
| DE602008021800C5 (de) | 2022-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2009019230A3 (en) | Use of procalcitonin (pct) in risk stratification and prognosis of patients with a primary, non-infectious disease | |
| CY1122973T1 (el) | Συνθεση υγρου διαπιδυσης η οποια περιλαμβανει ουσιες αναστολης της κρυσταλλωσης | |
| DE602006019262D1 (de) | QUANTITATIVE ASSAYS FÜR PDGFR-beta- IN KÖRPERFLÜSSIGKEITEN | |
| BRPI0816597A2 (pt) | "composto, composição farmacêutica, combinação, uso de um composto, método para tratar um indivíduo aflifido com uma consição patológica ou doença e método de modulação de uma atividade um receptor b2 adrenérgico" | |
| NZ609493A (en) | Diagnosis and treatments relating to th2 inhibition | |
| DE602006011896D1 (de) | Diagnoseverfahren für erkrankungen im zusammenhang mit hirnschäden | |
| MX382244B (es) | Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales | |
| BR112012012610A2 (pt) | terapia de combinação para o tratamento de câncer e ensaios diagnósticos para o uso na mesma | |
| WO2014036495A3 (en) | Diagnostic assays and kits for detection of folate receptor 1 | |
| PL2894162T3 (pl) | Identyfikacja związanych z nowotworem antygenów do diagnozowania i leczenia | |
| BRPI1011564A8 (pt) | Fio de material de sutura cirúrgica, kit cirúrgico e método para produzir fio | |
| NO20091630L (no) | CCR2-antagonister for behandling av fibrose | |
| MX2009005941A (es) | Ensayos de diagnostico complementario para terapia de cancer. | |
| EP4177234A4 (de) | Kalzinierter zirkonoxidkörper zur zahnärztlichen verwendung | |
| MX2010010799A (es) | Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea. | |
| BR112017004729A2 (pt) | processo de tratamento de doenças causadas por metástase óssea, medicamentos para as mesmas e processo de previsão do resultado clínico de tratamento de doenças causadas por metástase óssea | |
| MX2012005388A (es) | Reactivos y metodos para detectar globulos blancos pnh tipo ii y su identificacion como factores de riesgo para transtornos trombolicos. | |
| EP1937831A4 (de) | Verwendung von n-myristoyltransferase auf nichttumorgewebe zur krebsdiagnose | |
| CY1111602T1 (el) | ΜΕΘΟΔΟΣ ΓΙΑ ΤΗΝ ΑΝΙΧΝΕΥΣΗ ΤΗΣ ΔΡΑΣΤΙΚΟΤΗΤΑΣ IN VIVO ΤΗΣ ΝΕΥΡΟΤΡΥΨΙΝΗΣ, ΧΡΗΣΗ ΤΗΣ ΜΕΘΟΔΟΥ ΚΑΙ ΧΡΗΣΗ TOY C-ΤΕΡΜΑΤΙΚΟΥ 22-kDa ΘΡΑΥΣΜΑΤΟΣ ΤΗΣ ΑΓΡΙΝΗΣ ΩΣ ΒΙΟΔΕΙΚΤΗ ΕΙΣ ΤΗΝ ΔΙΑΓΝΩΣΗ ΚΑΙ ΠΑΡΑΚΟΛΟΥΘΗΣΗ ΔΙΑΤΑΡΑΧΩΝ ΠΟΥ ΕΧΟΥΝ ΣΧΕΣΗ ΜΕ ΝΕΥΡΟΤΡΥΨΙΝΗ | |
| DE602006020850D1 (de) | Biomarker zur diagnose einer herzerkrankung sowie verwendung davon | |
| FR2917172B1 (fr) | Methode de mesure de l'activite plasmine des microparticules presentes dans un echantillon de fluide biologique et utilisation | |
| CL2013000595A1 (es) | Metodo de diagnostico in vitro para determinar si un paciente con cancer es susceptible al tratamiento con un inhibidor de la proteina tirosina quinasa 2 (ptk2); kit farmaceutico que comprende un inhibidor de ptk2; uso de un anticuerpo de e-cadherina para diagnostico en vivo. | |
| ATE518536T1 (de) | Medizinische verwendung von 3-(2,2,2- trimethylhydrazinium) propionathydrogenfumarat und dihydrogenphosphat | |
| BR112013015394A2 (pt) | método de determinar a presença ou a ausência, em uma amostra biológica de um paciente, de células de câncer de bexiga ou próstata, composto, e, uso de um composto | |
| Vatrika et al. | IMPORTANCE OF RADIOLOGICAL TEMPLATING IN HIP ARTHROPLASTY: 1085 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 2174143 Country of ref document: EP |